EUVIMEDEUVIMED entdecken
Crossref

TMEM199 promotes PD-L1 expression and tumor immune evasion by activating the recycling of IFNGR1/2

Ting Li, Miner Xie, Ruhua Zhang, Jianliang Zhong, Zhenxuan Chen, Jiahui Lin, Yezi Zou, Yuanzhong Wu, Tiebang Kang, Liwen Zhou

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2025.218187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Ting Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center f…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Membrane Proteins, Tumor Escape, Receptors, Interferon. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Sun Yat-sen University Cancer Center, National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade (ICB) therapies targeting the programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) axis provide significant clinical benefits across multiple tumor types. Although interferon (IFN)-γ is essential for anti-tumor immunity, sustained IFN-γ signaling in the tumor microenvironment potently upregulates PD-L1 expression in tumor cells and induces profound T cell exhaustion, limiting the efficacy of ICB therapies. Therefore, further investigation into the regulation of IFN-γ-PD-L1 signaling is necessary for the development of more effective therapeutic strategies. Herein, transmembrane protein 199 (TMEM199) is identified as a novel regulator of IFN-γ-driven PD-L1 transcription. Mechanistically, TMEM199 and its important partner coiled-coil domain containing 115 (CCDC115) interact with IFNGR1/2 and facilitate their trafficking to RAB11A-positive recycling endosomes. TMEM199/CCDC115 also recruits transport protein particle (TRAPP) Ⅱ to the recycling endosomes and activates RAB11A, leading to enhanced IFNGR1/2 recycling and downstream PD-L1 upregulation. Collectively, these findings reveal that TMEM199 might be a promising therapeutic target for immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenMembrane ProteinsTumor EscapeReceptors, InterferonNeoplasmsHumansCell Line, TumorInterferon gamma ReceptorTumor MicroenvironmentAnimalsMiceGene Expression Regulation, NeoplasticSignal TransductionInterferon-gammaEndosomes

Stichwörter der Autor:innen

IFNGR1/2PD-L1RecyclingTMEM199

Substanzen

B7-H1 AntigenMembrane ProteinsCD274 protein, humanInterferon gamma ReceptorReceptors, InterferonInterferon-gamma

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR…

Förderung

  • Sun Yat-sen University Cancer Center
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Li, T., Xie, M., Zhang, R., Zhong, J., Chen, Z., Lin, J., Zou, Y., Wu, Y., Kang, T., & Zhou, L. (2026). TMEM199 promotes PD-L1 expression and tumor immune evasion by activating the recycling of IFNGR1/2. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.218187

Vancouver

Li T, Xie M, Zhang R, Zhong J, Chen Z, Lin J, et al. TMEM199 promotes PD-L1 expression and tumor immune evasion by activating the recycling of IFNGR1/2. Cancer Letters. 2026. doi:10.1016/j.canlet.2025.218187

BibTeX
@article{Li2026,
  author = {Li, Ting and Xie, Miner and Zhang, Ruhua and Zhong, Jianliang and Chen, Zhenxuan and Lin, Jiahui and Zou, Yezi and Wu, Yuanzhong and Kang, Tiebang and Zhou, Liwen},
  title = {TMEM199 promotes PD-L1 expression and tumor immune evasion by activating the recycling of IFNGR1/2},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2025.218187}
}
Kostenlos starten →